Product Code: RP-ID-10352087 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10352087
Market Overview:
Global Human Growth Hormone Market Analysis & Outlook 2030
In 2021, the global market size of human growth hormone is estimated to be USD 5 billion with the compound annual growth rate which is expected to be 9% during the forecast period 2022-2030. Factors such as the investment of market participants, the existence of a strong project portfolio, extensive research and development activities, a strong product portfolio, and the increase in government initiatives are expected to significantly promote the development of the market. Human (HGH), also known as growth hormone, is a peptide responsible for stimulating human growth, cell reproduction and cell regeneration, and is therefore important for human development. When the pituitary gland cannot synthesize a sufficient concentration of hGH, human growth hormone (GH) deficiency occurs.
Recombinant human growth hormone is administered by subcutaneous injection to treat this defect in humans. Several genetic diseases, including Prader-Willi syndrome and Turner syndrome, can also cause human growth hormone deficiency, leading to delayed puberty and lower-than-average height. It is a rare disease that affects less than one in 3,000 to 10,000 children in the United States. Currently, bodybuilders and athletes widely abuse hGH as an anti-aging treatment and performance-enhancing anabolic drugs for the elderly. However, HGH is a controlled substance under the US Food and Drug Administration (USFDA) and has not been approved for anti-aging and performance-enhancing indications.
A strong product portfolio and extensive R&D activities for the development of new growth hormone therapies are expected to be the main drivers of the human growth hormone market. For example, in September 2018, Novo Nordisk announced the Phase II clinical trial data of its research GH therapy Somapacitan, which is suitable for the treatment of growth hormone deficiency in children. In addition, in May 2019, Ascendis Pharma A/S announced the results of its Phase III clinical trial of TransCon hGH, which is suitable for children with growth hormone deficiency. Similarly, several major players, including Teva Pharmaceutical Industry Co., Ltd.; OPKO Health Company; Eli Lilly and Company; Ferring Pharmaceuticals; Sanofi; and LG Life Sciences participate in research and development activities to develop new human growth hormone therapies. In addition, initiatives taken by various government and private organizations to promote GH deficiency and human growth hormone therapy are expected to boost the market.
Every year, the International Alliance of Endocrinology Patient Support Organizations (ICOSEP), a non-profit charity headquartered in the United States, celebrates International Childhood Awareness Day to spread awareness of the early diagnosis and treatment of human growth hormone disorders, especially children. During the forecast period, the high cost of hGH therapy and various hGH-related adverse effects may hinder the development of the market. For example, according to UPMC Childrens Hospital in Pittsburgh, possible side effects of GH hormone treatment include knee, hip, or other joint pain; allergic reactions, including skin rash, swelling, or hives; and elevated blood sugar levels.
Application insight:
In 2020, GH lacks the largest market share in the market segment and is expected to maintain its dominant position during the forecast period. This can be attributed to the increased awareness of the early diagnosis and treatment of human GH deficiency and the introduction of new drugs in the hGH market. For example, in October 2018, Ascendis Pharma A/S received Orphan Drug Designation from the European Commission (EC) for its long-acting GH therapy TransCon hGH for human research, which is suitable for the treatment of GH deficiency in children. Ferring Pharmaceuticals Incs new recombinant HGH Zomacton (growth hormone) has been approved by the U.S. Food and Drug Administration for the treatment of GH-deficient adults. The GH deficiency market segment is further subdivided into adult GH deficiency and childhood GH deficiency. Due to the increasing number of drugs under development, the latter is expected to dominate the market during the forecast period.
For example, in October 2019, Pfizer and its partner OPKO Health Inc. announced that their phase III study investigated growth hormone in prepubertal hGH children and reached the primary endpoint of non-inferior daily growth hormone. The syndrome accounts for the second largest market share and is expected to become a lucrative market segment during the forecast period. This can be attributed to the increased efforts of various public and private organizations to increase awareness of the early diagnosis and treatment of Turner syndrome. Non-profit organizations such as the Turner Syndrome Support Association (UK), the American Turner Syndrome Association, and the Turner Syndrome Foundation celebrate "Turner Syndrome Awareness Month" every February and launch a national campaign to spread the word Awareness of disease.
Regional information:
Due to favorable reimbursement programs, mature medical infrastructure, important government initiatives, and increased awareness of health care, North America is estimated to account for the largest share. In addition, due to the presence of major players in the region, increased access to new drugs supports the North American market. Pfizer; Eli Lilly; and Genentech are some of the major players based in the United States that provide a wide range of human GH therapies in the region. The Asia-Pacific region is expected to record a significant compound annual growth rate during the forecast period. Major players are focused on gaining considerable market share in potential Asia-Pacific countries/regions such as Japan and China by obtaining approvals and launching new products. For example, in March 2017, the Danish pharmaceutical company Novo Nordisk A/S started its phase III clinical trial of HGH somapacitan in Japan, which is suitable for the treatment of adult growth hormone deficiency.
Human growth hormone market share outlook:
Some of the major players operating in the market are Novo Nordisk A/S; Pfizer; Eli Lilly; Sandoz International GmbH (Novartis AG); Merck; Genentech (Roche); Hui Ling Pharmaceutical; Teva Pharmaceutical Industry Co., Ltd.; and Ipsen. Several companies focus on the development of long-acting human growth hormone. Major companies operating in the market are adopting mergers, alliances, and acquisitions as key strategies to expand their geographic coverage and provide access to their solutions. For example, in October 2018, Novo Nordisk signed an agreement with Strongbridge Biopharma to acquire the rights of MACRILEN in the United States and Canada. MACRILEN (macimorelin) is the first and only oral drug approved by the FDA for the diagnosis of adult growth hormone deficiency.
Market segments covered by the report:
This report forecasts global, regional and national revenue growth, and analyzes the latest industry trends and opportunities in each market segment from 2022-2030. For the purpose of this research, Kenneth Research conducted a segmented report on the global human growth hormone market based on applications, distribution channels and regions: Application Outlook (Revenue, USD million, 2022-2030) Adult hormone deficiency growth rate (GH) GH deficiency in children GH deficiency Turner syndrome idiopathic short stature Prader-Willi syndrome smaller than gestational age Other distribution channel outlook (revenue, million dollars, 2022-2030) Hospital pharmacy retail pharmacy online pharmacy professional pharmacy.
Related Reports
Proof of Quality & Reliability
